์คํผ๋ก๋ ธ๋ฝํค
์คํผ๋ก๋ ธ๋ฝํค์ ํฉ์ฑ **์๋์คํ ๋ก ๊ธธํญ์ **์ด์ ์นผ๋ฅจ ๋ณด์กด ์ด๋จ์ ์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก ์ธํ์ฑ ์ฌ๋ถ์ (CHF), ๋ณต์, ์ ์ ๊ณ ํ์ ๋ฐ ์๋ฐ์ฑ ์๋์คํ ๋ก ์ฆ(ํนํ ๊ณ ์์ด)์ ๋ณด์กฐ ์น๋ฃ์ ๋ก ์ฌ์ฉ๋ฉ๋๋ค. **์์ ์์ ๋ฐ ์ฝ๋ฆฌํ์ ๋ฐฐ๊ฒฝ:** * **์๋์คํ ๋ก ํํผ(Aldosterone Escape):** ํธ๋ก์ธ๋ฏธ๋์ ๊ฐ์ ๋ฃจํ ์ด๋จ์ ์ ๋นํด ์ง์ ์ ์ธ ์ด๋จ ํจ๊ณผ๋ ์ฝํ์ง๋ง, ๋ ๋-์์ง์คํ ์ -์๋์คํ ๋ก ๊ณ(RAAS)๋ฅผ ์ฐจ๋จํ๋ ๋ฐ ์ค์ํ ์ญํ ์ ํฉ๋๋ค. ACE ์ต์ ์ ๋ฅผ ๋ณต์ฉ ์ค์ธ ํ์๋ผ๋ ๊ฒฐ๊ตญ ์๋์คํ ๋ก ์์น๊ฐ ๋ค์ ๋ฐ๋ฑํ ์ ์๋๋ฐ(์๋์คํ ๋ก ํํผ ํ์), ์คํผ๋ก๋ ธ๋ฝํค์ ์ด๋ฅผ ์ํํฉ๋๋ค. * **์ฌ๊ทผ ๋ณดํธ:** ์ธ์ํ์์๋ ์ฌ๊ทผ์ ์ฌ์ ํ๋ฅผ ๋ฐฉ์งํ๊ณ ํด๋ก์ด ์ฌ์ฅ ๋ฆฌ๋ชจ๋ธ๋ง์ ์๋ฐฉํ๋ ํจ๊ณผ๋ก ๋์ด ํ๊ฐ๋ฐ๊ณ ์์ต๋๋ค. ์์ํ(์: ์ ์ก์ข ์ฑ ์น๋ชจํ ์งํ์ด ์๋ ๊ฐ)์์ ์ด ์ด์ ์ ์ ๋์ ๋ํด์๋ ๋ ผ๋์ด ์์ง๋ง, ํ์ค ๋ค์ ๋ณ์ฉ CHF ํ๋กํ ์ฝ์ ์ ์ ๋ ๋ง์ด ํฌํจ๋๊ณ ์์ต๋๋ค. * **์์ฒด์ด์ฉ๋ฅ :** ์์๊ณผ ํจ๊ป ํฌ์ฌํ ๋ ํก์์จ์ด ํฌ๊ฒ ํฅ์๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Spironolactone acts as a competitive antagonist at the **mineralocorticoid receptor**. * **Mechanism:** It competitively inhibits **aldosterone** binding in the distal renal tubules and collecting ducts. * **Pathway:** Blockade of the receptor โ prevents the synthesis of aldosterone-induced proteins (such as Na+/K+ ATPase and epithelial sodium channels) โ **decreases sodium and chloride reabsorption** while **decreasing potassium, ammonium, and phosphate excretion**. * **Result:** Mild diuresis with potassium retention. It does not affect carbonic anhydrase or proximal renal transport mechanisms.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- As a diuretic in CHF (when furosemide and ACE inhibitors alone do not control fluid accumulation) ยท 1-2 mg/kg PO q12h ยท PO ยท q12h ยท Refractory CHF
- As a diuretic in CHF (when serum potassium is low) ยท 1 mg/kg q12h PO ยท PO ยท q12h
- For adjunctive treatment of hypertension ยท 1-2 mg/kg PO q12h ยท PO ยท q12h
- For adjunctive treatment of hypertension (Step 3 drug) ยท 1-2 mg/kg twice daily ยท PO ยท q12h ยท When systolic BP >160 mmHg, diastolic >120 mmHg after amlodipine and ACE inhibitor.
- For adjunctive treatment of primary hyperaldosteronism ยท 1-2 mg/kg PO twice daily ยท PO ยท q12h ยท If potassium supplementation alone does not control clinical signs.
- Congestive heart failure, ascites, hyperaldosteronism ยท 2-4 mg/kg ยท PO ยท q24h ยท Continuous ยท Severe ulcerative facial dermatitis has been reported in Maine Coon cats.
- As a diuretic in CHF (when furosemide and ACE inhibitors alone do not control fluid accumulation) ยท 1-2 mg/kg PO q12h ยท PO ยท q12h ยท Refractory CHF
- As a diuretic in CHF (with other diuretics when hypokalemia is an issue) ยท 2-4 mg/kg PO once daily ยท PO ยท q24h
- As a diuretic in CHF (to allow further reduction of furosemide dose) ยท 0.5 mg/kg PO once daily to 2 mg/kg twice daily ยท PO ยท q24h to q12h ยท 0.5 mg/kg once daily for aldosterone blockage (weak diuretic effect); 2 mg/kg twice daily for stronger diuretic effect.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hyperkalemia
- Addison's disease (hypoadrenocorticism)
- Anuria
- Acute renal failure
- Significant renal impairment
- Hypoadrenocorticism
- Hyperkalaemia
- Hyponatraemia
- Concurrent use with NSAIDs in animals with renal insufficiency
- Pregnancy
- Lactation
- Animals intended for breeding
์ด์๋ฐ์
- Facial dermatitis (notably reported in Maine Coon cats)
- Hyperkalemia
- Hyponatremia
- Dehydration
- Increased BUN and mild acidosis (in patients with renal impairment)
- Gastrointestinal distress (vomiting, anorexia)
- CNS effects (lethargy, ataxia)
- Endocrine changes (anti-androgenic effects, e.g., gynecomastia in humans, feminization of male fetuses)
- Hyponatraemia
- Hyperkalaemia
- Reversible prostatic atrophy (in entire male dogs)
- Severe ulcerative facial dermatitis (in Maine Coon cats)
- Hepatotoxicity (reported in humans)
์ฝ๋ฌผ ์ํธ์์ฉ
- Digoxin ยท Spironolactone may increase the half-life of digoxin; enhanced monitoring of digoxin serum levels is warranted. May also cause falsely elevated digoxin values if using a radioimmune assay (RIA). ยท moderate
- Mitotane ยท Spironolactone may mute the effects of mitotane if given concurrently; monitor carefully.
- Neuromuscular blockers, non-depolarizing ยท Possible increase in neuromuscular blockade effects.
- Potassium-sparing diuretics (e.g., triamterene) ยท Increased risk of hyperkalemia.
- Potassium supplements ยท Increased risk of hyperkalemia. ยท major
- Salicylates (e.g., Aspirin) ยท Spironolactone's diuretic effects may be decreased if administered concomitantly.
- Thiazide diuretics ยท Potentiates diuretic effects ยท moderate
- Loop diuretics ยท Potentiates diuretic effects ยท moderate
- ACE inhibitors ยท Increased risk of hyperkalaemia (though generally safe to use concurrently in practice; monitor potassium) ยท moderate
- NSAIDs ยท Increased risk of hyperkalaemia and nephrotoxicity ยท major
- Ciclosporin ยท Increased risk of hyperkalaemia ยท moderate
๋ชจ๋ํฐ๋ง
- Serum electrolytes (especially potassium and sodium)
- BUN and creatinine
- Hydration status
- Blood pressure (if indicated)
- Clinical signs of edema/ascites
- Patient weight
- Serum potassium
- Serum sodium
- Renal function (BUN, Creatinine)
- Digoxin levels (if used concurrently)
๊ณผ์ฉ๋
Information on acute overdosage of spironolactone in veterinary patients is limited. * **Management:** Should an acute overdose occur, follow general guidelines for diuretic overdose (e.g., furosemide or chlorothiazide). * **Treatment:** Empty the stomach if ingestion was recent. Provide supportive care, monitor hydration status, and closely evaluate serum electrolytes (especially potassium and sodium). * Contact an animal poison control center for further guidance.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.